BioInvent (Q3 Update): Phase II in NSCLC up and Running - Redeye
Bildkälla: Stockfoto

BioInvent (Q3 Update): Phase II in NSCLC up and Running - Redeye

Redeye reviews BioInvent's Q3 report 2025. The company is doubling down on BI-1206 and BI-1808. BI-1808 has two important readouts scheduled in Q4 2025, as does the BI-1206 triple combination.

Börsvärldens nyhetsbrev